SCHEMBL353828

SCHEMBL353828

CNC(=O)c1ccccc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.70
STAT3 P40763 1/20 0.66
HPGD P15428 3/20 0.65
TP53 P04637 1/20 0.65
GLA P06280 1/20 0.65
RAB9A P51151 3/20 0.64
NPC1 O15118 2/20 0.64
PLK1 P53350 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.62
KCNK3 O14649 1/20 0.62
KCNK9 Q9NPC2 1/20 0.62
GAA P10253 2/20 0.60
LMNA P02545 2/20 0.60
MAPT P10636 1/20 0.60
TSHR P16473 1/20 0.60
MAPK1 P28482 1/20 0.60
HSD17B10 Q99714 1/20 0.60
RXFP1 Q9HBX9 1/20 0.60
ALDH1A1 P00352 1/20 0.58
POLB P06746 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7476155 0.98 CTSD (0.68) CTSDSTAT3HPGDTP53GLA
Alcohol SCHEMBL6834845 0.94 CTSD (0.69) CTSDSTAT3HPGDTP53GLA
SCHEMBL2646539 0.86 KAT2B (0.57) CTSDSTAT3HPGDTP53GLA
SCHEMBL23084665 0.85 STAT3 (0.72) CTSDSTAT3RAB9ANPC1SMN1; SMN2
SCHEMBL6671288 0.84 CTSD (0.70) CTSDSTAT3HPGDTP53GLA
SCHEMBL2646534 0.84 KAT2B (0.55) CTSDSTAT3HPGDTP53GLA
SCHEMBL29097559 0.83 CTSD (0.51) CTSDSTAT3HPGDTP53GLA
SCHEMBL17544377 0.83 TAS1R3 (0.61) CTSDHPGDTP53GLARAB9A
SCHEMBL1534502 0.83 RAB9A (0.61) HPGDTP53RAB9ANPC1PLK1
SCHEMBL5954008 0.83 PLK1 (0.54) CTSDPLK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 US claimed
CN-111868063-B PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2023-08-01 CN claimed
US-10016448-B2 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity MERCK PATENT GMBH (DE) 2018-07-10 US claimed
US-9732032-B2 3-aminocyclopentane carboxamide derivatives MERCK PATENT GMBH (DE) 2017-08-15 US claimed
US-20170136048-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY MERCK PATENT GMBH (DE) 2017-05-18 US claimed
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-15 US claimed
EP-4695246-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES Syngenta Crop Protection AG (CH) 2026-02-18 EP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
EP-4612134-A1 DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 EP disclosed
CN-115536681-B Method for selectively synthesizing p-pinacol boron ester substituted anisole compound 广西科学院 2024-12-24 CN disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 US disclosed
WO-2024213653-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-10-17 WO disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-5597845-A TACHYKININ ANTAGONISTS MERRELL PHARMACEUTICALS INC. (US) 1997-01-28 US disclosed
US-5589489-A Cyclic amide derivatives for treating asthma ZENECA LIMITED (GB) 1996-12-31 US disclosed
WO-1996032385-A1 NOVEL SUBSTITUTED PIPERAZINE DERIVATIVES HAVING TACHYKININ RECEPTOR ANTAGONISTS ACTIVITY HOECHST MARION ROUSSEL, INC. (US) 1996-10-17 WO disclosed
EP-0734383-A1 CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS ZENECA LIMITED (GB) 1996-10-02 EP disclosed
WO-1995035279-A1 SUBSTITUTED ALKYLDIAMINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS MERRELL PHARMACEUTICALS INC. (US) 1995-12-28 WO disclosed
WO-1995016682-A1 CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS ZENECA LIMITED (GB) 1995-06-22 WO disclosed
US-3959269-A TRANQUILIZERS, SEDATIVES SANDOZ, INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES FADS1, FASN, FFAR3 CTSD 3001/4885STAT3 2331/4885HPGD 2008/4885
US-10016448-B2 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity BTK, SYK, LCK CTSD 3276/4885STAT3 912/4885HPGD 2169/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 CTSD 3428/4885STAT3 637/4885HPGD 591/4885
US-20170136048-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY BTK, SYK, LCK CTSD 3276/4885STAT3 912/4885HPGD 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.